Abstract: The present invention relates to a host cell, which comprises under the control of a heterologous promoter a polynucleotide comprising a nucleotide sequence encoding a polypeptide capable of synthesizing a polysaccharide consisting of a dimeric repeating unit as well as to a vaccine composition comprising such host cell. Furthermore, either such host cell or a polypeptide expressed by such host cell is used for the production of a polysaccharide consisting of a dimeric repeating unit which may be used as a glycoconjugate vaccine.

Abstract: The present application provides for the use of S100A8 or S100A9 homodimer or S100A8/A9 heterodimer in the prevention or treatment of a NF-?B-associated postnatal inflammatory disorder in a newborn subject. Moreover, the present invention relates to a pharmaceutical composition comprising S100A8 or S100A9 homodimer or S100A8/A9 heterodimer and an in vitro method for evaluating the risk of a newborn subject for developing a NF-?B-associated postnatal inflammatory disorder.

Abstract: The present invention relates to an inhibitor of miR-671-5p for use in a method of preventing or treating fibrosis. Further, the present invention encompasses a kit comprising said inhibitor of miR-671-5p. The present invention also relates to an in vitro method for identifying a compound for preventing or treating fibrosis.

Abstract: The invention relates to implants that are implanted into living beings as temporary implants and that disintegrate in the body through biological adsorption over a period of time, in addition to a process for producing aforesaid implants. The implant according to the invention consists of magnesium or a magnesium master alloy. It is formed from fibers of magnesium or a magnesium master alloy that are connected to one another through sintering bridges that are locally spaced vis-à-vis each other and form an open-pored body. The fibers may be produced with the help of the melt extraction process and may subsequently be sintered with one another.

Abstract: The method for preparing a tissue construct for medical purposes uses endothelial progenitor cells (EPC) which have not been passaged multiple times and have a content of EOEC (early outgrowth endothelial progenitor cells) and LOEC (late outgrowth endothelial progenitor cells). These cells and fibroblasts and/or muscle cells, viz. myoblasts, myofibroblasts, smooth muscle cells or the progenitors thereof, are, in the form of living cells, seeded onto a matrix or introduced into a matrix in order to yield the tissue construct following further treatment steps. The matrix is preferably a protein preparation, more particularly a fibrinogen preparation. Both the cells and the fibrinogen preparation can be obtained from a single blood sample from a patient. Apart from the preparation of bypass materials, prosthetic vascular graft, tissue patches, conduits and the like, the EOEC-containing EPC culture or suspension is suitable as means for cell transplantation.

Abstract: The method for preparing a tissue construct for medical purposes uses endothelial progenitor cells (EPC) which have not been passaged multiple times and have a content of EOEC (early outgrowth endothelial progenitor cells) and LOEC (late outgrowth endothelial progenitor cells). These cells and fibroblasts and/or muscle cells, viz. myoblasts, myofibroblasts, smooth muscle cells or the progenitors thereof, are, in the form of living cells, seeded onto a matrix or introduced into a matrix in order to yield the tissue construct following further treatment steps. The matrix is preferably a protein preparation, more particularly a fibrinogen preparation. Both the cells and the fibrinogen preparation can be obtained from a single blood sample from a patient. Apart from the preparation of bypass materials, prosthetic vascular graft, tissue patches, conduits and the like, the EOEC-containing EPC culture or suspension is suitable as means for cell transplantation.

Abstract: The method for preparing a tissue construct for medical purposes uses endothelial progenitor cells (EPC) which have not been passaged multiple times and have a content of EOEC (early outgrowth endothelial progenitor cells) and LOEC (late outgrowth endothelial progenitor cells). These cells and fibroblasts and/or muscle cells, viz. myoblasts, myofibroblasts, smooth muscle cells or the progenitors thereof, are, in the form of living cells, seeded onto a matrix or introduced into a matrix in order to yield the tissue construct following further treatment steps. The matrix is preferably a protein preparation, more particularly a fibrinogen preparation. Both the cells and the fibrinogen preparation can be obtained from a single blood sample from a patient. Apart from the preparation of bypass materials, prosthetic vascular graft, tissue patches, conduits and the like, the EOEC-containing EPC culture or suspension is suitable as means for cell transplantation.

Abstract: A method of processing model data representing a body section with bilateral symmetry of a biological organism is proposed that comprises the steps of providing object imaging data representing the body section having one or more defect portions; calculating a longitudinal axis and a lateral axis of the body section based on mathematical analysis of the object imaging data; and determining a mirror plane based on the calculated longitudinal and lateral axes. Said mirror plane allows for reconstructing the one or more defect portions by mirroring one or more corresponding portions having no defects at the mirror plane.

Abstract: The method for preparing a tissue construct for medical purposes uses endothelial progenitor cells (EPC) which have not been passaged multiple times and have a content of EOEC (early outgrowth endothelial progenitor cells) and LOEC (late outgrowth endothelial progenitor cells). These cells and fibroblasts and/or muscle cells, viz. myoblasts, myofibroblasts, smooth muscle cells or the progenitors thereof, are, in the form of living cells, seeded onto a matrix or introduced into a matrix in order to yield the tissue construct following further treatment steps. The matrix is preferably a protein preparation, more particularly a fibrinogen preparation. Both the cells and the fibrinogen preparation can be obtained from a single blood sample from a patient. Apart from the preparation of bypass materials, prosthetic vascular graft, tissue patches, conduits and the like, the EOEC-containing EPC culture or suspension is suitable as means for cell transplantation.

Abstract: The invention relates to implants that are implanted into living beings as temporary implants and that disintegrate in the body through biological adsorption over a period of time, in addition to a process for producing aforesaid implants. The implant according to the invention consists of magnesium or a magnesium master alloy. It is formed from fibers of magnesium or a magnesium master alloy that are connected to one another through sintering bridges that are locally spaced vis-à-vis each other and form an open-pored body. The fibers may be produced with the help of the melt extraction process and may subsequently be sintered with one another.

Abstract: A method of generating model data representing a body section of a biological organism, like e.g., a head or part thereof, a joint, or soft tissue, includes the steps of providing object data representing a first portion of the body section, providing standard data representing a complete standard body section, and subjecting the standard data to a registration process, wherein the model data to be generated are created by adapting the standard data to the object data, said model data representing the first portion of the body section and a second portion of the body section.